Drug Profile


Alternative Names: Anti-CD4 monoclonal antibody IDEC-CE9.1; CE9.1; IDEC-CE9.1; PRIMATIZED anti-CD4 antibody IDEC-CE9.1; SB 210396

Latest Information Update: 15 May 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IDEC Pharmaceuticals
  • Developer GlaxoSmithKline; IDEC Pharmaceuticals
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 15 May 2001 Discontinued-III for Asthma in USA (Unknown route)
  • 15 May 2001 Discontinued-III for Rheumatoid arthritis in USA (Infusion)
  • 15 May 2001 Discontinued-Preclinical for Rheumatoid arthritis in Japan (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top